Publications by authors named "W A SCHROEDER"

Background: Esophageal cancer (EC) is a disease with a poor prognosis. While treatment options have been improved, there is no consensus for surveillance strategies following therapy with curative intent. As the incidence of EC is rising and a large fraction of patients will experience disease recurrence, the need for evidence-based treatment and optimal surveillance is evident.

View Article and Find Full Text PDF

The most common functional challenge after Ivor-Lewis esophagectomy is delayed emptying of the gastric conduit. One of the primary endoscopic treatment strategies is performing a pyloric dilatation. However, the effects of dilation have never been scientifically proven.

View Article and Find Full Text PDF

Stoichiometric genome-scale metabolic models (generally abbreviated GSM, GSMM, or GEM) have had many applications in exploring phenotypes and guiding metabolic engineering interventions. Nevertheless, these models and predictions thereof can become limited as they do not directly account for protein cost, enzyme kinetics, and cell surface or volume proteome limitations. Lack of such mechanistic detail could lead to overly optimistic predictions and engineered strains.

View Article and Find Full Text PDF
Article Synopsis
  • - Esophageal adenocarcinoma (EAC) is a highly lethal cancer with a low 5-year survival rate, and few personalized treatment options exist due to limited understanding of its subgroups.
  • - A study identified a rare subgroup of EAC patients (about 0.7% of 826 studied) characterized by distinct morphological and immunohistochemical features, including clear cytoplasm in tumor cells and expression of specific fetal gut proteins like SALL4.
  • - These tumors may have genetic alterations linked to tumor suppression and show potential for CAR T cell therapy, indicating a step towards personalized treatment in this specific subtype according to WHO classification.
View Article and Find Full Text PDF

Introduction: In esophageal cancer, histopathologic response following neoadjuvant therapy and transthoracic esophagectomy is a strong predictor of long-term survival. At the present, it is not known whether the initial tumor volume quantified by computed tomography (CT) correlates with the degree of pathologic regression.

Methods: In a retrospective analysis of a consecutive patient cohort with esophageal adenocarcinoma, tumor volume in CT prior to chemoradiotherapy or chemotherapy alone was quantified using manual segmentation.

View Article and Find Full Text PDF